KPRX
Kiora Pharmaceuticals, Inc.
Price Chart
Latest Quote
$2.55
-0.04 (-1.54%)
Current Price
| Previous Close | $2.59 |
| Open | $2.58 |
| Day High | $2.60 |
| Day Low | $2.52 |
| Volume | 38,690 |
Stock Information
| Shares Outstanding | 4.43M |
| Total Debt | $374K |
| Cash Equivalents | $13.87M |
| Net Income | $-11.06M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $11.30M |
| EPS (TTM) | $-2.70 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-2.20M |
| Income | $-11.06M |
| Book/sh | $3.49 |
| Cash/sh | $3.13 |
| Employees | 13 |
Financial Ratios
| Quick Ratio | 6.19 |
| Current Ratio | 6.68 |
| Debt/Eq | 2.68 |
Returns & Margins
| ROA | -22.41% |
| ROE | -58.78% |
Ownership
| Insider Ownership | 3.05% |
| Institutional Ownership | 28.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.14 |
| P/B | 0.73 |
Analyst Data
| Recommendation | buy |
| Target Price | $12.00 |
Technical Indicators
| SMA20 | $2.61 |
| SMA50 | $2.54 |
| SMA200 | $2.32 |
| RSI | 45.65 |
| ATR | 0.1311 |
| Shares Float | 4.30M |
| Short Float | 0.42% |
| Short Ratio | 0.28 |
| Volatility | -0.38 |
| Rel Volume | 1.31 |
Performance History
| Week | -0.78% |
| Month | -5.56% |
| Quarter | +25.00% |
| 6 Months | +18.06% |
| YTD | +26.24% |
| Year | -16.94% |
| 3 Years | -60.65% |
| 5 Years | -99.84% |
| 10 Years | -99.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $2.55 | 38,690 |
| 2026-06-24 | $2.59 | 25,700 |
| 2026-06-23 | $2.60 | 26,000 |
| 2026-06-22 | $2.47 | 20,500 |
| 2026-06-18 | $2.53 | 95,500 |
| 2026-06-17 | $2.57 | 14,800 |
| 2026-06-16 | $2.62 | 46,200 |
| 2026-06-15 | $2.46 | 46,200 |
| 2026-06-12 | $2.55 | 23,800 |
| 2026-06-11 | $2.60 | 6,800 |
| 2026-06-10 | $2.63 | 12,800 |
| 2026-06-09 | $2.59 | 30,000 |
| 2026-06-08 | $2.58 | 19,700 |
| 2026-06-05 | $2.50 | 15,900 |
| 2026-06-04 | $2.63 | 31,400 |
| 2026-06-03 | $2.68 | 17,600 |
| 2026-06-02 | $2.72 | 13,900 |
| 2026-06-01 | $2.81 | 34,000 |
| 2026-05-29 | $2.68 | 45,400 |
| 2026-05-28 | $2.83 | 27,700 |
| 2026-05-27 | $2.79 | 36,500 |
| 2026-05-26 | $2.70 | 75,700 |
About Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has a strategic development and commercialization agreement with ThÊa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $16,000,000 | $0 | $0 |
| Operating Revenue | $0 | $16,000,000 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $19,960 | $21,446 | $11,132 | $8,599 |
| Total Expenses | $9,459,247 | $10,419,181 | $8,690,183 | $11,726,918 |
| Other Income Expense | $-3,532,098 | $-1,152,484 | $-3,896,251 | $-2,017,994 |
| Other Non Operating Income Expenses | $-160,272 | $26,073 | $28,841 | $-14,498 |
| Net Non Operating Interest Income Expense | $874,042 | $1,231,403 | $162,857 | $48,292 |
| Interest Expense Non Operating | $19,960 | $21,446 | $11,132 | $8,599 |
| Operating Expense | $9,459,247 | $10,419,181 | $8,690,183 | $11,726,918 |
| General And Administrative Expense | $5,745,087 | $5,542,324 | $4,663,146 | $8,277,993 |
| Other Operating Expenses | - | $-20,000 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,835,154 | $3,594,733 | $-12,513,896 | $-13,583,610 |
| Net Interest Income | $874,042 | $1,231,403 | $162,857 | $48,292 |
| Interest Income | $894,002 | $1,252,849 | $173,989 | $56,891 |
| Normalized Income | $-7,817,370 | $4,345,945 | $-9,413,073 | $-11,637,214 |
| Net Income From Continuing And Discontinued Operation | $-10,835,154 | $3,594,733 | $-12,513,896 | $-13,583,610 |
| Total Operating Income As Reported | $-12,831,073 | $4,510,288 | $-12,586,896 | $-12,309,523 |
| Net Income Common Stockholders | $-10,835,154 | $3,594,733 | $-13,044,881 | $-13,583,610 |
| Net Income | $-10,835,154 | $3,594,733 | $-12,513,896 | $-13,583,610 |
| Net Income Including Noncontrolling Interests | $-10,835,154 | $3,594,733 | $-12,513,896 | $-13,583,610 |
| Net Income Continuous Operations | $-10,835,154 | $3,594,733 | $-12,513,896 | $-13,583,610 |
| Pretax Income | $-12,117,303 | $5,659,738 | $-12,423,577 | $-13,696,620 |
| Special Income Charges | $-3,371,826 | $-1,178,557 | $-3,925,092 | $-578,394 |
| Interest Income Non Operating | $894,002 | $1,252,849 | $173,989 | $56,891 |
| Operating Income | $-9,459,247 | $5,580,819 | $-8,690,183 | $-11,726,918 |
| Per Share | ||||
| Diluted EPS | $-2.64 | $0.87 | $-24.25 | $-166.95 |
| Basic EPS | $-2.60 | $0.93 | $-24.25 | $-166.95 |
| Other | ||||
| Tax Effect Of Unusual Items | $-354,042 | $-427,345 | $-824,269 | $-57,100 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,700,716 | $6,878,946 | $-8,435,555 | $-11,642,916 |
| Total Unusual Items | $-3,371,826 | $-1,178,557 | $-3,925,092 | $-2,003,496 |
| Total Unusual Items Excluding Goodwill | $-3,371,826 | $-1,178,557 | $-3,925,092 | $-2,003,496 |
| Reconciled Depreciation | $24,801 | $19,205 | $51,798 | $41,609 |
| EBITDA (Bullshit earnings) | $-12,072,542 | $5,700,389 | $-12,360,647 | $-13,646,412 |
| EBIT | $-12,097,343 | $5,681,184 | $-12,412,445 | $-13,688,021 |
| Diluted Average Shares | $4,166,692 | $4,125,075 | $538,007 | $81,366 |
| Basic Average Shares | $4,166,692 | $3,872,644 | $538,007 | $81,366 |
| Diluted NI Availto Com Stockholders | $-10,835,154 | $3,594,733 | $-13,044,881 | $-13,583,610 |
| Tax Provision | $-1,282,149 | $2,065,005 | $90,319 | $-113,010 |
| Gain On Sale Of Ppe | $0 | $-3,859 | $-28,379 | $4,211 |
| Write Off | $4,624,000 | $2,008,000 | $1,904,314 | $0 |
| Impairment Of Capital Assets | $0 | $104,167 | - | $0 |
| Restructuring And Mergern Acquisition | $-1,252,174 | $-937,469 | $1,992,399 | $582,605 |
| Research And Development | $3,714,160 | $4,896,857 | $4,027,037 | $3,448,925 |
| Selling General And Administration | $5,745,087 | $5,542,324 | $4,663,146 | $8,277,993 |
| Other Gand A | $5,745,087 | $5,542,324 | $4,663,146 | $8,277,993 |
| Otherunder Preferred Stock Dividend | - | $0 | $530,985 | $0 |
| Gain On Sale Of Security | - | - | - | $-1,425,102 |
| Gain On Sale Of Business | - | - | - | - |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $14,063,436 | $19,072,676 | $-2,704,196 | $664,436 |
| Total Assets | $24,253,300 | $36,484,484 | $13,711,870 | $18,678,259 |
| Total Non Current Assets | $2,504,852 | $6,778,472 | $8,973,838 | $10,997,593 |
| Other Non Current Assets | $64,253 | $28,970 | $45,034 | $82,260 |
| Goodwill And Other Intangible Assets | $2,063,100 | $6,687,100 | $8,813,850 | $10,743,164 |
| Other Intangible Assets | $2,063,100 | $6,687,100 | $8,813,850 | $10,743,164 |
| Current Assets | $21,748,448 | $29,706,012 | $4,738,031 | $7,680,666 |
| Other Current Assets | $1,141,804 | $2,042,487 | $233,382 | $343,069 |
| Prepaid Assets | $201,332 | $0 | - | - |
| Receivables | $3,316,229 | $871,443 | $2,049,965 | $1,373,041 |
| Other Receivables | $1,522,770 | $601,197 | - | - |
| Taxes Receivable | $1,793,459 | $270,246 | $2,049,965 | $1,373,041 |
| Cash Cash Equivalents And Short Term Investments | $17,089,083 | $26,792,082 | $2,454,684 | $5,964,556 |
| Cash And Cash Equivalents | $8,696,570 | $3,792,322 | $2,454,684 | $5,964,556 |
| Debt | ||||
| Total Debt | $368,259 | $57,170 | $106,891 | $105,782 |
| Long Term Debt And Capital Lease Obligation | $203,798 | $33,815 | $59,822 | $0 |
| Current Debt And Capital Lease Obligation | $164,461 | $23,355 | $47,069 | $105,782 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,126,764 | $10,724,708 | $7,602,216 | $7,270,659 |
| Total Non Current Liabilities Net Minority Interest | $4,495,266 | $4,715,995 | $5,968,221 | $3,998,296 |
| Other Non Current Liabilities | $2,939,316 | $4,191,490 | $5,128,959 | $3,309,175 |
| Non Current Deferred Liabilities | $1,352,152 | $490,690 | $779,440 | $689,121 |
| Non Current Deferred Taxes Liabilities | $102,152 | $490,690 | $779,440 | $689,121 |
| Current Liabilities | $3,631,498 | $6,008,713 | $1,633,995 | $3,272,363 |
| Payables And Accrued Expenses | $3,467,037 | $5,985,358 | $1,586,926 | $2,844,196 |
| Payables | $1,202,402 | $2,743,632 | $206,260 | $1,008,262 |
| Total Tax Payable | $142,096 | $2,328,042 | $0 | - |
| Income Tax Payable | $142,096 | $2,328,042 | $0 | - |
| Accounts Payable | $1,060,306 | $415,590 | $206,260 | $1,008,262 |
| Other Current Liabilities | - | - | - | $322,385 |
| Equity | ||||
| Common Stock Equity | $16,126,532 | $25,759,772 | $6,109,650 | $11,407,600 |
| Preferred Stock Equity | $4 | $4 | $4 | - |
| Total Equity Gross Minority Interest | $16,126,536 | $25,759,776 | $6,109,654 | $11,407,600 |
| Stockholders Equity | $16,126,536 | $25,759,776 | $6,109,654 | $11,407,600 |
| Gains Losses Not Affecting Retained Earnings | $-246,137 | $-282,159 | $-182,801 | $-182,741 |
| Other Equity Adjustments | $-246,137 | $-282,159 | $-182,801 | $-182,741 |
| Retained Earnings | $-154,217,276 | $-143,382,122 | $-146,976,855 | $-134,462,959 |
| Other | ||||
| Ordinary Shares Number | $3,761,739 | $3,000,788 | $856,182 | $199,607 |
| Share Issued | $3,761,739 | $3,000,788 | $856,182 | $199,607 |
| Tangible Book Value | $14,063,432 | $19,072,672 | $-2,704,200 | $664,436 |
| Invested Capital | $16,126,532 | $25,759,772 | $6,109,650 | $11,407,600 |
| Working Capital | $18,116,950 | $23,697,299 | $3,104,036 | $4,408,303 |
| Capital Lease Obligations | $368,259 | $57,170 | $106,891 | $105,782 |
| Total Capitalization | $16,126,536 | $25,759,776 | $6,109,654 | $11,407,600 |
| Additional Paid In Capital | $170,314,656 | $169,156,374 | $153,192,228 | $146,035,314 |
| Capital Stock | $275,293 | $267,683 | $77,082 | $17,986 |
| Common Stock | $275,289 | $267,679 | $77,078 | $17,986 |
| Preferred Stock | $4 | $4 | $4 | $0 |
| Non Current Deferred Revenue | $1,250,000 | $0 | - | - |
| Long Term Capital Lease Obligation | $203,798 | $33,815 | $59,822 | $0 |
| Current Capital Lease Obligation | $164,461 | $23,355 | $47,069 | $105,782 |
| Current Accrued Expenses | $2,264,635 | $3,241,726 | $1,380,666 | $1,835,934 |
| Net PPE | $377,499 | $62,402 | $114,954 | $172,169 |
| Accumulated Depreciation | $-25,912 | $-1,024 | $-6,289 | $-117,319 |
| Gross PPE | $403,411 | $63,426 | $121,243 | $289,488 |
| Leases | $110,789 | $0 | $0 | $22,569 |
| Other Properties | $285,827 | $57,170 | $118,722 | $205,391 |
| Machinery Furniture Equipment | $6,795 | $6,256 | $2,521 | $61,528 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $8,392,513 | $22,999,760 | $0 | - |
| Goodwill | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-10,071,965 | $8,552,859 | $-9,556,951 | $-10,428,133 |
| Operating Activities | ||||
| Operating Cash Flow | $-9,961,176 | $8,559,115 | $-9,556,951 | $-10,428,133 |
| Cash Flow From Continuing Operating Activities | $-9,961,176 | $8,559,115 | $-9,556,951 | $-10,428,133 |
| Operating Gains Losses | $-2,371 | $-759 | $-25,503 | $1,420,891 |
| Investing Activities | ||||
| Capital Expenditure | $-110,789 | $-6,256 | - | - |
| Investing Cash Flow | $14,426,645 | $-22,662,611 | $0 | $6,375 |
| Cash Flow From Continuing Investing Activities | $14,426,645 | $-22,662,611 | $0 | $6,375 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $14,998,865 | $6,967,310 | $5,377,719 |
| Financing Cash Flow | $265,655 | $15,498,155 | $5,966,066 | $8,620,921 |
| Cash Flow From Continuing Financing Activities | $265,655 | $15,498,155 | $5,966,066 | $8,620,921 |
| Net Common Stock Issuance | $0 | $14,998,865 | $6,967,310 | $5,362,090 |
| Common Stock Issuance | $0 | $14,998,865 | $6,967,310 | $5,377,719 |
| Net Other Financing Charges | - | $-1,190,049 | $-1,308,323 | - |
| Repurchase Of Capital Stock | - | - | $0 | $-15,629 |
| Other | ||||
| Repayment Of Debt | $-2,750,000 | $0 | - | $0 |
| Issuance Of Debt | $2,750,000 | $0 | - | - |
| End Cash Position | $8,701,137 | $3,796,379 | $2,458,951 | $6,013,816 |
| Beginning Cash Position | $3,796,379 | $2,458,951 | $6,013,816 | $7,899,690 |
| Effect Of Exchange Rate Changes | $173,634 | $-57,231 | $36,020 | $-85,037 |
| Changes In Cash | $4,731,124 | $1,394,659 | $-3,590,885 | $-1,800,837 |
| Proceeds From Stock Option Exercised | $265,655 | $1,689,339 | $307,079 | $3,258,831 |
| Net Issuance Payments Of Debt | $0 | $0 | - | $0 |
| Net Long Term Debt Issuance | $0 | $0 | - | $0 |
| Long Term Debt Payments | $-2,750,000 | $0 | - | $0 |
| Long Term Debt Issuance | $2,750,000 | $0 | - | - |
| Net Investment Purchase And Sale | $14,537,434 | $-22,656,355 | $0 | - |
| Sale Of Investment | $22,713,285 | $12,976,020 | $0 | - |
| Purchase Of Investment | $-8,175,851 | $-35,632,375 | $0 | - |
| Net PPE Purchase And Sale | $-110,789 | $-6,256 | $0 | $6,375 |
| Purchase Of PPE | $-110,789 | $-6,256 | $0 | $0 |
| Change In Working Capital | $-3,270,363 | $3,666,061 | $-1,821,952 | $668,513 |
| Change In Other Working Capital | $1,250,000 | - | - | - |
| Change In Other Current Liabilities | $-103,845 | $-46,500 | $584 | $-103,629 |
| Change In Other Current Assets | $-34,172 | $15,231 | $-7,583 | $-22,465 |
| Change In Payables And Accrued Expense | $-2,387,239 | $4,487,960 | $-1,267,729 | $1,392,182 |
| Change In Accrued Expense | $-3,512,167 | $4,261,841 | $-459,713 | $609,719 |
| Change In Payable | $1,124,928 | $226,119 | $-808,016 | $782,463 |
| Change In Account Payable | $1,124,928 | $226,119 | $-808,016 | $782,463 |
| Change In Prepaid Assets | $419,736 | $-1,823,897 | $885 | $275,161 |
| Change In Receivables | $-2,414,843 | $1,033,267 | $-548,109 | $-872,736 |
| Other Non Cash Items | $-901,363 | $-916,780 | $2,003,025 | $675,024 |
| Stock Based Compensation | $900,236 | $656,593 | $754,944 | $462,450 |
| Unrealized Gain Loss On Investment Securities | $-119 | $119 | $0 | - |
| Asset Impairment Charge | $4,624,000 | $2,112,167 | $1,904,314 | $0 |
| Amortization Of Securities | $-112,305 | $-283,474 | $0 | - |
| Deferred Tax | $-388,538 | $-288,750 | $90,319 | $-113,010 |
| Deferred Income Tax | $-388,538 | $-288,750 | $90,319 | $-113,010 |
| Depreciation Amortization Depletion | $24,801 | $19,205 | $51,798 | $41,609 |
| Depreciation And Amortization | $24,801 | $19,205 | $51,798 | $41,609 |
| Amortization Cash Flow | $24,801 | $19,205 | $51,798 | - |
| Amortization Of Intangibles | $24,801 | $19,205 | $51,798 | - |
| Gain Loss On Investment Securities | $-2,371 | $-4,519 | - | $1,425,102 |
| Gain Loss On Sale Of PPE | $0 | $3,760 | $28,379 | $-4,211 |
| Net Income From Continuing Operations | $-10,835,154 | $3,594,733 | $-12,513,896 | $-13,583,610 |
| Gain Loss On Sale Of Business | - | $0 | $-53,882 | $0 |
| Common Stock Payments | - | - | $0 | $-15,629 |
| Sale Of PPE | - | - | $0 | $6,375 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Depreciation | - | - | - | - |
Fetched: 2026-06-23